SPRO vs. ACRS, ONCY, LFVN, VACC, CMRX, BRNS, BTAI, MIST, ANVS, and PRPH
Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Aclaris Therapeutics (ACRS), Oncolytics Biotech (ONCY), LifeVantage (LFVN), Vaccitech (VACC), Chimerix (CMRX), Barinthus Biotherapeutics (BRNS), BioXcel Therapeutics (BTAI), Milestone Pharmaceuticals (MIST), Annovis Bio (ANVS), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical preparations" industry.
Spero Therapeutics (NASDAQ:SPRO) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends, risk and community ranking.
25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 4.5% of Spero Therapeutics shares are held by company insiders. Comparatively, 5.5% of Aclaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Spero Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.
Aclaris Therapeutics received 176 more outperform votes than Spero Therapeutics when rated by MarketBeat users. However, 69.31% of users gave Spero Therapeutics an outperform vote while only 66.96% of users gave Aclaris Therapeutics an outperform vote.
In the previous week, Spero Therapeutics had 10 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 12 mentions for Spero Therapeutics and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.34 beat Spero Therapeutics' score of 0.05 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.
Spero Therapeutics has a net margin of 21.09% compared to Aclaris Therapeutics' net margin of -248.28%. Spero Therapeutics' return on equity of 35.42% beat Aclaris Therapeutics' return on equity.
Spero Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 376.19%. Aclaris Therapeutics has a consensus target price of $22.25, suggesting a potential upside of 1,801.71%. Given Aclaris Therapeutics' higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Spero Therapeutics.
Spero Therapeutics has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Spero Therapeutics beats Aclaris Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Spero Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spero Therapeutics Competitors List
Related Companies and Tools
